Pharmacogenetic predictors of outcome in stage ii-iii colon cancer patients treated with oxaliplatin and fluoropyrimidines-based adjuvant chemotherapy

Authors and affiliations: Ana Custodio, Juan Moreno-Rubio, Jorge Aparicio, Javier Gallego-Plazas, Ricardo Yaya, Joan Maurel, Nuria Rodríguez-Salas, Emilio Burgos, David Ramos, Ana Calatrava, Encarna Andrada, Esther Díaz-López, Antonio Sánchez, Rosario Madero, Paloma Cejas , Jaime Feliu *Both authors have contributed equally to this work 1-Medical Oncology Department. La Paz University Hospital. IdiPaz. Madrid, Spain 2-Translational Oncology Unit. Medical Oncology Department. La Paz University Hospital. IdiPaz. Madrid, Spain 3Medical Oncology Department. La Fe University Hospital. Valencia, Spain 4-Medical Oncology Department. General University Hospital. Elche (Alicante), Spain 5Medical Oncology Department. Valencian Oncology Institute. Valencia, Spain 6Medical Oncology Department. Clinic University Hospital. Barcelona, Spain 7Pathology Department. La Paz University Hospital. IdiPaz. Madrid, Spain 8Pathology Department. La Fe University Hospital. Valencia, Spain 9Pathology Department. Valencian Oncology Institute. Valencia, Spain 10Pathology Department. General University Hospital. Elche (Alicante), Spain